Related Experiment Video

Updated: Aug 1, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

Dacarbazine (DTIC) in malignant melanoma: reduced toxicity with protection from light

O M Koriech, V S Shükla

    Clinical Radiology
    |January 1, 1981
    PubMed

    Insights

    Protecting dacarbazine (dimethyl triazeno imidazole carboxamide) from light significantly reduces side effects in advanced malignant melanoma patients. This photoprotection maintains treatment efficacy, with complete or partial responses observed in most patients.

    Area of Science:

    • Oncology
    • Pharmacology
    • Dermatology

    Background:

    • Dacarbazine (DTIC) is a key treatment for advanced malignant melanoma.
    • Significant side effects limit DTIC's clinical use.
    • Photodegradation of DTIC is implicated in its toxicity.

    Purpose of the Study:

    • To evaluate the impact of light protection on DTIC toxicity and efficacy.
    • To determine if photoprotection reduces adverse events without compromising treatment response.

    Main Methods:

    • Fifteen patients with metastatic malignant melanoma received DTIC.
    • Dacarbazine was administered with protection from light during preparation and administration.
    • Patient outcomes, including side effects and response rates, were monitored.

    Main Results:

    • No troublesome hematological or other side effects were reported with light-protected DTIC.
    • Complete disappearance of metastases occurred in 27% of patients.
    • Partial response was observed in 47% of patients, with notable efficacy in skin, lung, and liver lesions.

    Conclusions:

    • Protecting dacarbazine from light during administration is crucial for reducing toxicity.
    • Photoprotection of DTIC can minimize side effects while preserving or enhancing its therapeutic efficacy.
    • This approach offers a safer treatment strategy for advanced malignant melanoma.

    More Related Videos

    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

    Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

    Published on: June 7, 2019

    Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)04:12

    Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)

    Published on: December 19, 2019

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Skin Cancer01:30

    Skin Cancer

    Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
    Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...